Robert L Coleman

48PUBLICATIONS
214CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsComparative and cross-cultural education
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (48)

|Jul 10, 2026
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Apr 30, 2026
An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

|Jan 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Robert L Coleman, Rodney Rocconi, Bradley J Monk

|Jan 13, 2026
Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.

Allison L Brodsky, Amma Asare, Bryan Fellman

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

Pageof 8

Frequent Collaborators

8 joint publications

Bradley J Monk

6 joint publications

Ana Oaknin

6 joint publications

David M O'Malley

5 joint publications

Toon Van Gorp